Gene
GATA3
GATA3 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (63), Actionable biomarkers (1), Trial mentions (6), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention GATA3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 6 at the structurally incomplete recent edge.
GATA3 has 6 trial mentions across 5 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 35 of 11,460 | 0.31% |
| 2022 | 0 of 8,285 | 0.00% | 38 of 13,598 | 0.28% |
| 2021 | 0 of 8,692 | 0.00% | 32 of 15,045 | 0.21% |
| 2020 | 0 of 7,640 | 0.00% | 32 of 14,459 | 0.22% |
| 2019 | 0 of 7,300 | 0.00% | 34 of 12,159 | 0.28% |
| 2018 | 2 of 6,927 | 0.03% | 34 of 11,854 | 0.29% |
| 2017 | 0 of 6,558 | 0.00% | 29 of 11,595 | 0.25% |
Showing 10 of 37 years.
Assay-provider ledger (63)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| CytoBay, Inc | Diagnostic provider | Clinical validation | 1 | March 01, 2026 |
| Agilent | Reagent supplier | Clinical validationAnalytical validation | 3 | December 01, 2025 |
| BIOCARE MEDICAL LLC | Reagent supplier | Clinical validationAnalytical validation | 7 | December 01, 2025 +1 undated |
| Cytocell | Diagnostic provider | Analytical validation | 1 | December 01, 2025 |
| Epredia | Unclassified | Analytical validation | 1 | December 01, 2025 |
Showing 5 of 63 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| GATA3 oncogenic mutation | Aromatase Ihibitors | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (6)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02576665 | Trial eligibility (AACT) |
| NCT05932667 | Trial eligibility (AACT) |
| NCT03396471 | Trial eligibility (AACT) |
| NCT03452774 | Trial eligibility (AACT) |
| NCT00923845 | Trial outcomes (AACT) |
Showing 5 of 6 trial mentions.
Target-disease associations (1,081)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 15q11.2 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 16q24.3 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 17q21.31 microduplication syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 20p12.3 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
Showing 5 of 1,081 associations.
Vendor sourcing (37)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v4.1.0 dataset (total allele frequency: <0.001%). Predicted Consequence/Location: Framesh... | View ClinVar record SCV002318711.2 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.895C>T (p.R299W) alteration is located in exon 4 (coding exon 3) of the GATA3 gene. This alteration results from a C to T substitution at nucleotide po... | View ClinVar record SCV003547366.2 |
| Baylor College of Medicine | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | PM2 | View ClinVar record SCV005871217.1 |
| Centre Hospitalier Universitaire de Nantes | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001572250.1 |
| Centre Hospitalier Universitaire de Rennes | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV006064928.1 |
Showing 5 of 37 sourcing records.
Trial-cited literature (432)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Untangling obese asthma: Design of proof-of-concept study of semaglutide in poorly controlled asthma. | The journal of allergy and clinical immunology. Global | 2026 | 0 |
| Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients With and Without Comorbid Atopic Dermatitis. | Allergy | 2025 | 14 |
| Liver regeneration-associated machine learning architecture integrating time-phased predictions for post-hepatectomy liver failure. | EClinicalMedicine | 2025 | 1 |
| Single-cell RNA-seq analysis of longitudinal CD4<sup>+</sup> T cell samples reveals cell-type-specific changes during early stages of type 1 diabetes. | Genome medicine | 2025 | 0 |
| Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043. | Nature communications | 2024 | 9 |
Showing 5 of 432 papers.
Protein variant mentions (20)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A70D | 1 | 2018 | PMID 29349598 |
| p.C321S | 1 | 2015 | PMID 25741868 |
| p.D160E | 1 | 2015 | PMID 25741868 |
| p.D278N | 1 | 2015 | PMID 25741868 |
| p.G248R | 1 | 2015 | PMID 25741868 |
Showing 5 of 20 variants.
Human sample screening reference (3)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.M294K | CMI-MBC | Ductal and Lobular Neoplasms; Breast | 1 | 174 | 0.57% | 0.10% to 3.18% |
| p.M294K | CPTAC-2 | Not Reported; Cystic, Mucinous and Serous Neoplasms; Adenomas and Adenocarcinomas; Ductal and Lobular Neoplasms; Squamous Cell Neoplasms; Other and unspecified female genital organs; Colon; Breast; Retroperitoneum and peritoneum; Rectum; Ovary | 1 | 328 | 0.30% | 0.05% to 1.71% |
| p.M294K | TCGA-BRCA | Cystic, Mucinous and Serous Neoplasms; Adenomas and Adenocarcinomas; Fibroepithelial Neoplasms; Basal Cell Neoplasms; Ductal and Lobular Neoplasms; Epithelial Neoplasms, NOS; Squamous Cell Neoplasms; Complex Epithelial Neoplasms; Adnexal and Skin Appendage Neoplasms; Breast | 3 | 1,098 | 0.27% | 0.09% to 0.80% |
Literature-extracted relations (59)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Peptides | Chemical | negative_correlate |
Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. | 2020 |
| Hydroxychloroquine | Chemical | positive_correlate |
Immunomodulatory effects of hydroxychloroquine on Th1/Th2 balance in women with repeated implantation failure. | 2018 |
| (R)- nicotine | Chemical | associate |
The impact of the effectiveness of GATA3 as a prognostic factor in breast cancer. | 2018 |
| CURCUMIN | Chemical | associate |
The impact of the effectiveness of GATA3 as a prognostic factor in breast cancer. | 2018 |
| Calcium/Vitamin D | Chemical | associate |
Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism. | 2011 |
Showing 5 of 59 relation assertions.
Organizations publishing (496)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 27 | 2000 to 2026 |
| Memorial Sloan Kettering Cancer Center | Hospital | 15 | 2013 to 2020 |
| Mayo Clinic | Hospital | 12 | 2010 to 2022 |
| Mass General Brigham | Hospital | 11 | 2014 to 2022 |
| Novant Health | Hospital | 11 | 2012 to 2020 |
Showing 5 of 496 organizations.
Where GATA3 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
1,007 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.